PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and c ...

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on treatments for inflammatory bowel disease (IBD) including ulcerative colitis (UC) and fibrostenotic Crohn's disease Key Milestones and Catalysts - Completion of a Phase 1B cohort in fibrostenotic Crohn's disease with results expected in early Q1 2026 [6] - Filing of an Investigational New Drug (IND) application for a definitive UC study, anticipated to start mid-year 2026 [6][7] - Final top-line readout for the UC study scheduled for the end of 2027 [7] Product Mechanism and Differentiation - **Product**: PALI-2108, a PDE4 inhibitor designed as a prodrug for optimized local delivery in the gut [9] - Unique formulation allows for once-daily dosing, targeting the terminal ileum and colon, which is not available with other PDE4 inhibitors [11] - The prodrug is activated by gut bacteria, minimizing systemic exposure and associated adverse effects [11][12] - Demonstrated 100% clinical response and 40% clinical remission in a small cohort of UC patients after one week of treatment [24] Clinical Data and Efficacy - Historical data shows a 31% clinical remission rate for Apremilast and a 57% rate for Mefenilast, while PALI-2108 showed a 100% clinical response in a five-patient cohort [14][15] - Significant biomarker improvements observed: 70% reduction in fecal calprotectin, 15% reduction in CRP, and a 70% increase in cyclic AMP after one week of treatment [15] - The drug is reported to be 20 times more potent than Apremilast, allowing for higher dosing without increased toxicity [17] Safety and Tolerability - Emphasis on safety and tolerability as key differentiators in the market, especially compared to JAK inhibitors and S1Ps which have safety warnings [22][37] - Ongoing studies aim to demonstrate safety and tolerability in symptomatic fibrostenotic Crohn's patients with ileal lesions [44] Future Development Plans - Phase 2 study design includes 195 patients with a focus on individual patient dosing adaptation after the first three weeks [30] - The study aims to establish safety, tolerability, and efficacy, with potential for accelerated approval based on surrogate biomarkers [49] - Current cash position is strong with $138 million raised, providing sufficient runway for Phase 2 studies in both UC and fibrostenotic Crohn's disease [50] Market Opportunity - High unmet medical need in fibrostenotic Crohn's disease with limited competition and no current approvals for anti-inflammatory, antifibrotic treatments [42][43] - The company is positioned uniquely as the only candidate targeting both anti-inflammatory and antifibrotic pathways in this indication [43] Conclusion - Palisade Bio is poised for significant developments in 2026 with promising clinical data, a strong financial position, and a unique product offering that addresses critical needs in the treatment of IBD [51]

Core Insights - PALI-2108 has shown safety and tolerability with no serious adverse events, supporting its potential as a once-daily oral therapy for ulcerative colitis and fibrostenotic Crohn's disease [1][2][3] Clinical Data Summary - Phase 1b study demonstrated a 100% clinical response rate in patients with moderate-to-severe ulcerative colitis, with significant histological and biomarker improvements [2][4] - Key findings from the Phase 1b study include a mean reduction of 62.8% in the modified Mayo score and a decrease in fecal calprotectin in 4 out of 5 patients [4] - Phase 1a study confirmed extended drug exposure with colon tissue drug concentrations remaining above target levels for over 36 hours post-dose, supporting a once-daily dosing regimen [5][10] Mechanism of Action - PALI-2108 is designed to selectively inhibit PDE4 in the distal ileum and colon, utilizing a microbiome-activated mechanism to enhance local bioactivation and minimize systemic exposure [7] - The drug demonstrated significant immunomodulatory effects, including a 40% average reduction in tissue lymphocytes and a 51% decrease in PDE4B expression [4][10] Future Development Plans - The company plans to submit an Investigational New Drug (IND) application for a Phase 2 study in the first half of 2026, following the completion of ongoing studies [1][5]

Summary of Palisade Bio (PALI) Conference Call - February 19, 2025 Company Overview - **Company**: Palisade Bio (PALI) - **Industry**: Biotechnology, specifically focusing on treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease Core Points and Arguments 1. **Drug Development**: - PALI-2108 is a PDE4 inhibitor formulated as a prodrug, originally developed in Merck labs, designed to be more potent than previous inhibitors for treating ulcerative colitis and Crohn's disease [3][4] - The prodrug formulation minimizes systemic exposure, allowing the drug to reach the distal ileum in the colon, targeting the disease more effectively [4] 2. **Market Opportunity**: - Nearly 1 million patients in the U.S. suffer from ulcerative colitis, with 55% experiencing moderate to severe cases [5] - Current treatments have less than a 20% success rate and often come with poor safety profiles, highlighting the need for better options [5] 3. **Phase One Study Results**: - Preliminary data from the single ascending dose (SAD) study showed that PALI-2108 was well tolerated across all doses (15 mg to 450 mg) with no serious adverse events or treatment-related laboratory abnormalities [6] - Mild treatment-emergent adverse events were noted only at the highest dose, indicating a favorable safety profile [6] 4. **Market Size and Deal Activity**: - The global ulcerative colitis market is currently valued at over $7 billion and is projected to exceed $9 billion by 2028 [7] - There have been 70 deals in the IBD space over the last five years, with an average deal value of $1.2 billion, indicating strong investor interest and potential for growth [7][8] 5. **Second Drug Development**: - PALI-1908, another drug in development, utilizes the same active PDE4 inhibitor as PALI-2108 but is designed to release the drug in the terminal ileum, targeting fibrosis in Crohn's patients [9] - Initial data suggests that PALI-2108 may also be effective for treating fibrotic Crohn's disease, potentially reducing the need for a separate drug development process [9] Additional Important Information - The company emphasizes the importance of oral delivery for patient compliance and preference, which is a significant advantage over current treatment options [4] - The favorable safety profile and targeted delivery mechanism of PALI-2108 are expected to provide a competitive edge in the market [6][7] - The company plans to provide further updates on the development of PALI-2108 and its potential applications in treating Crohn's disease in the coming months [9]